The multicenter.

In June 2011, Alkermes announced data from a stage 1b double-blind, randomized, placebo-controlled clinical study of ALKS 9070 in 32 individuals with schizophrenia. Data from the analysis showed that ALKS 9070 was generally well tolerated and accomplished therapeutically relevant plasma concentrations of aripiprazole with a pharmacokinetic profile that helps once-monthly dosing. Alkermes’ expertise in developing safe and effective long-performing therapeutics uniquely positions us to build up a once-monthly atypical antipsychotic medicine that delivers aripiprazole, a prescribed oral item with an established protection and efficacy profile broadly, mentioned Dr. Continue reading